ReviewPostepy dermatologii i alergologii2017
The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors.
Review in Postepy dermatologii i alergologii, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Best evidence summary for the management of epidermal growth factor receptor inhibitor-induced skin toxicity symptoms in cancer patients.Frontiers in medicine · 2025Pooled it
- Corrective and Restorative Dermatology in Cancer Survivors: An Urgent Unmet Need!American journal of clinical dermatology · 2026Review
- Risk factors for skin rash among patients with cancer receiving epidermal growth factor receptor inhibitors: a scoping review protocol.BMJ open · 2026Article
- Managing skin-related adverse events during mirdametinib treatment for NF1-PNs: expert guidance from the ReNeu trial.Frontiers in oncology · 2026Review
- Cutaneous Adverse Effects of EGFR Therapy in Breast Cancer Treatment.Clinical and translational science · 2025Review
- Case Report: Two cases of staged combined treatment for complex skull-exposing wounds: synergistic effects of mechanical tension and moist wound healing.Frontiers in medicine · 2025Article
- Best evidence summary for preventing and preventing epidermal growth factor receptor inhibitors induced paronychia in cancer patients.Frontiers in oncology · 2025Article
- Article
- Integrating network pharmacology and experimental models to investigate the efficacy and mechanism of Tiansha mixture on xerosis.Archives of dermatological research · 2024Article
- Stevens-Johnson Syndrome Caused by Enzalutamide: A Case Report and Literature Review.Frontiers in oncology · 2021Article
- Dermatologic Toxicities of Targeted Therapy and Immunotherapy in Head and Neck Cancers.Frontiers in oncology · 2021Review
- Epidermal growth factor receptor (EGFR) inhibitor induced purpuric drug eruption: Three case reports.Medicine · 2019Article
- Overall clinical and trichoscopic analysis performed in patients who underwent pressurized intraperitoneal aerosol chemotherapy (PIPAC) treatment for peritoneal carcinomatosis - initial trial preliminary report.Postepy dermatologii i alergologii · 2019Article
- Antitumor pharmacotherapy of colorectal cancer in kidney transplant recipients.Therapeutic advances in medical oncology · 2019Review
- EGFR inhibitors: clinical aspects, risk factors and biomarkers for acneiform eruptions and other mucosal and cutaneous adverse effects.Anais brasileiros de dermatologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Overexpression of the epidermal growth factor receptor (EGFR) is found in many cancers, including those of the head and neck area, non-small-cell lung cancer, and colorectal, cervical, prostate, breast, ovary, stomach, and pancreatic cancer. The EGFR inhibitors are used at present in the treatment of such cancers. Skin lesions that develop during and after cancer treatment may be due to specific cytostatics, molecular-targeted drugs, radiation therapy, complementary therapy, or the cancer itself, and hence knowledge is essential to distinguish between them. The mechanism through which skin toxicity arises during treatment with EGFR inhibitors is not well known, but seems to be due to the modification of the RAS/RAF/MEK/ERK signal path associated with its activation, which results in the similarity between the adverse effects of EGFR inhibitors and the treatment of melanoma with BRAF and MEK inhibitors. The most common side effects are pruritus, xerosis, papulopustular rash, hand-foot skin reaction, alopecia and dystrophy of the hair, and paronychia. This work presents options for prevention and suggestions for managing these adverse events, which are of importance in the care of patients undergoing oncological treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.